[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial

16 Aug 2024
[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial
American Society of Clinical Oncology (ASCO) 2024: 5-year data from the international, randomized, open-label phase III CROWN trial comparing lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small-cell lung cancer (NSCLC) demonstrate unprecedented progression-free survival (PFS) with lorlatinib.
This special report is supported by an education grant from the industry. 

Resources

[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial

[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial

[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial

[Infographics] 1L lorlatinib achieves longest ever PFS in ALK+ NSCLC: 5-year data from the CROWN trial